Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline

Hiromasa Inoue, Masashi Komori, Takafumi Matsumoto, Satoru Fukuyama, Mikiko Matsumura, Takako Nakano, Miyuki Tsuda, Koichiro Matsumoto, Akiko Kanaya, Atsushi Moriwaki, Hisamichi Aizawa, Makoto Yoshida, Yoichi Nakanishi

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β2-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 μg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV1. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV1 increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.

Original languageEnglish
Pages (from-to)611-616
Number of pages6
Issue number6
Publication statusPublished - Nov 2007

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline'. Together they form a unique fingerprint.

Cite this